Welcome to our dedicated page for Ccc Intelligent Solutions Hld news (Ticker: CCC), a resource for investors and traders seeking the latest updates and insights on Ccc Intelligent Solutions Hld stock.
CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCC) is the parent of CCC Intelligent Solutions Inc., a SaaS and cloud platform provider focused on the property and casualty insurance economy. News about CCC typically highlights developments in its technology platform, relationships with insurers and automotive ecosystem participants, and capital markets activity related to its listed shares.
Company press releases describe CCC Intelligent Solutions Inc. as operating the CCC Intelligent Experience (IX) Cloud platform, which uses AI and an event-based architecture to connect more than 35,000 businesses, including insurers, repairers, automakers and part suppliers. News coverage often includes announcements about new platform capabilities, such as the CCC OEM Link Network, which is presented as an offering to support OEM collision certification programs. For example, Nissan is identified as the first automaker to join the CCC OEM Link Network, with CCC managing certified network operations, shop audits, billing processes and communications between Nissan and its certified repairers.
Investors and industry participants following CCC-related news can also expect updates on share repurchase authorizations, accelerated share repurchase programs and secondary offerings by existing stockholders. These announcements provide insight into the company’s capital allocation decisions and changes in ownership by major shareholders. Together, technology updates and financial announcements form the core of CCC’s news flow.
This news page aggregates such releases and related coverage so readers can review developments around CCC’s SaaS platform, its role in the P&C insurance and collision repair ecosystem, and transactions involving its common stock. Users interested in CCC’s evolving partnerships, product offerings and shareholder-related actions can consult this feed for company-issued updates and market-facing announcements.
Clarivate Plc (NYSE:CCC) released a report emphasizing the growing prevalence of research malpractice, posing a threat to scientific literature integrity. The report urges collaboration among stakeholders to establish ethical guidelines aimed at maintaining research integrity in a challenging environment. It identifies the rise in deviant publication practices and suggests leveraging technology and analytics for improvement. Key parties involved include researchers, journals, publishers, institutions, funders, and governments, all of whom have vested interests in preserving research quality.
Summary not available.
Summary not available.
Clarivate Plc (NYSE: CCC) announced the integration of Darts-ip case law data with the Innography IP analytics solution, enhancing strategic decision-making in intellectual property management. This follows the acquisition of CPA Global, which expanded the firm's capabilities, offering multi-jurisdictional litigation data from 141 countries and insights from over 1.8 million patent cases. The integration aims to support patent research, competitive intelligence, and litigation strategies, ultimately helping clients lower costs and make informed decisions across the IP lifecycle.
Summary not available.
Clarivate Plc (NYSE: CCC) has completed its acquisition of CPA Global, creating a significant intellectual property (IP) entity. This merger aims to enhance IP-related products and services for a global customer base. Jerre Stead, Executive Chairman of Clarivate, emphasized the advantages of combined resources to identify opportunities and reduce risks in innovation. Former CPA Global CEO Simon Webster expressed confidence in forming a global IP leader. The acquisition involved approximately 217 million shares, granting CPA Global shareholders 35% ownership in Clarivate.
Clarivate secured $1.6 billion in financing to address CPA Global’s $2 billion debt.
Clarivate Plc (NYSE: CCC) will release its third-quarter 2020 financial results on October 29, before the market opens. The earnings release and supplementary financial information will be available on the investor website. A conference call and webcast to discuss the results will occur at 8:00 AM Eastern Time on the same day. Interested parties can access the live audio by dialing designated numbers for the U.S., Canada, and international callers. An audio replay will be available for two weeks following the call.
Clarivate Plc has partnered with the Open Access Monitor in Germany to provide Web of Science data, promoting open access research in the DACH region (Germany, Austria, Switzerland). This initiative, supported by the German Federal Ministry of Education and Research, will enhance data collection on publication financing and trends. Clarivate aims to bolster its commitment to open research and community-driven projects, having previously integrated open access data into its citation indexes, now exceeding 12 million articles. This collaboration aims to facilitate better informed, data-driven decisions in the research community.
Clarivate Plc (NYSE:CCC) released the 2020 Pharmaceutical R&D Factbook, highlighting a decrease in global R&D spending to $80 billion in 2022, down from a predicted $86 billion. This marks the first decline since 2016, influenced by COVID-19 and its impact on drug development. Notably, the average drug development time decreased from 14.5 years in 2010 to 10.2 years in 2019. However, new molecular entity (NME) launches have dropped 22% since 2018, with the U.S. seeing a 25% decrease in launches, while China and Japan increased their NME launches by 11% since 2017.
Clarivate Plc (NYSE: CCC) has announced the naming of 24 new Citation Laureates, highlighting researchers whose work is considered 'Nobel class'. This year's honorees come from countries including the USA, Canada, Germany, Japan, South Korea, and the UK. Since 2002, Clarivate has recognized researchers based on citation data from the Web of Science, with only 5,700 papers cited over 2,000 times. To date, 54 Citation Laureates have received a Nobel Prize. Notable mention includes advances in personalized medicine, gender pay gap studies, and galaxy formation.